{"id":"W1966629200","doi":"10.1016/j.eururo.2008.07.026","title":"Re: Bevacizumab plus Interferon alfa-2a for Treatment of Metastatic Renal Cell Carcinoma: A Randomised, Double-Blind Phase III Trial","year":2008,"lang":"en","type":"letter","venue":"European Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Renal cell carcinoma; Bevacizumab; Oncology; Internal medicine; Interferon alfa; Interferon; Urology; Chemotherapy; Immunotherapy; Cancer; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000465733,0.001183758,0.003273903,0.0006996042,0.0001362291,0.0000241474,0.0004147182,0.0004705139,0.0003699315],"category_scores_gemma":[0.000064635,0.000911025,0.001549263,0.0001917844,0.0003784403,0.00005245048,0.0001168219,0.0007706679,0.0001565904],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007165266,"about_ca_system_score_gemma":0.0006179479,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001075873,"about_ca_topic_score_gemma":0.00001136865,"domain_scores_codex":[0.9938931,0.001204306,0.0019132,0.001415894,0.0005563797,0.001017045],"domain_scores_gemma":[0.9959234,0.000867647,0.001170959,0.001495136,0.0002558183,0.0002870408],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7320153,0.001503972,0.000002202929,0.0003031818,0.001128465,0.01510056,0.0009229161,0.00001361806,0.0004625826,0.000001411371,0.2475861,0.0009596523],"study_design_scores_gemma":[0.6400213,0.05081619,0.000003404506,0.00002444565,0.00495456,0.00067237,0.00002046627,0.00004315693,0.003587297,0.00000428931,0.2994755,0.0003770526],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.830867,0.01117923,0.001103226,0.08741695,0.003028323,0.03058513,0.0008066745,0.0002411257,0.03477234],"genre_scores_gemma":[0.9075639,0.0005209873,0.0010619,0.04642659,0.009422376,0.001656134,0.00861852,0.000713842,0.02401577],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09199399,"threshold_uncertainty_score":0.999334,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09391503087787555,"score_gpt":0.3151565272663038,"score_spread":0.2212414963884283,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}